Start Up Spotlight: SurgiMab Aims For First-In-Market Tumor-Detecting Fluorescent Probe For FGS
Executive Summary
SurgiMab is aiming for its lead product, SGM-101, to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS). Based in Montpellier, France, the company has initiated a Phase III trial to assess the clinical benefit of using FGS with SGM-101 as the intraoperative imaging agent to identify cancer lesions during colorectal surgery.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.